ESPR (ESPR)
Drug Manufacturers - Specialty & Generic
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Market Cap
—
P/E (TTM)
—
EPS
—
Div Yield
—
52W Range
—
Beta
—
Company overview
Live quote temporarily unavailable — press releases and news are still shown below.
No company overview is available for ESPR yet.
Peers in Drug Manufacturers - Specialty & Generic
All in industry →TAK#1
Takeda Pharmaceutical Company Limited
$57.78B-1.07%
ZTS#2
Zoetis Inc.
$50.46B+0.20%
HLN#3
Haleon plc
$43.61B+0.40%
TEVA#4
Teva Pharmaceutical Industries Limited
$36.05B+1.44%
UTHR#5
United Therapeutics Corporation
$25.19B-1.19%
VTRS#6
Viatris Inc.
$15.85B+0.29%
RGC#7
Regencell Bioscience Holdings Limited
$13.93B-2.46%
NBIX#8
Neurocrine Biosciences, Inc.
$13.21B-1.13%
ELAN#9
Elanco Animal Health Incorporated
$11.66B-0.59%
RDY#10
Dr. Reddy's Laboratories Limited
$10.92B+0.15%
Recent press releases
ESPR has not issued a press release in this window.
SEC filings
All filings →ESPR has not filed an SEC document in this window.
Insider trades
All insider trades →ESPR has no reported insider trades in the last 90 days.
Institutional holders
All holders →As of 2025-12-31 · prior 2025-09-30
BlackRock, Inc.$65.4M
17,682,201 sh+19.2%
D. E. Shaw & Co., Inc.$25.5M
6,903,483 sh+3208.9%
VANGUARD GROUP INC$55.3M
14,945,454 sh+23.6%
ORBIMED ADVISORS LLC$22.1M
5,965,498 sh● NEW
Two Seas Capital LP$44.0M
11,902,521 sh+22.1%
WASATCH ADVISORS INC$34.9M
9,445,759 sh+33.8%
Eversept Partners, LP$14.2M
3,851,133 sh● NEW
MARSHALL WACE, LLP$20.2M
5,471,611 sh+117.0%
People at ESPR
All people →Quarterly financials
Full financials →Revenue trend
03/25
$29.4M
NI -$40.5M
06/25
$40.3M
NI -$12.7M
09/25
$87.3M
NI -$31.3M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.16
Prior: $-0.06
Revenue sparkline